Skip to main content
Erschienen in: Clinical Rheumatology 2/2024

13.12.2023 | Original Article

Respiratory infection risk in primary Sjögren’s syndrome complicated with interstitial lung disease: a retrospective study

verfasst von: Xingyu Zhou, Hao Li, Naidi Wang, Yuebo Jin, Jing He

Erschienen in: Clinical Rheumatology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To explore clinical and laboratory characteristics of primary Sjögren’s syndrome (pSS) complicated with interstitial lung disease (ILD) and investigate the risk factors for respiratory infections in pSS-ILD.

Methods

A cohort of 162 pSS-ILD patients in Peking University People’s Hospital from 2015 to 2020 were included, and all medical records were completely collected. We screened 53 patients suffering from respiratory infections as study cases, compared with 109 age- and sex-matched controls. Differences between infection group and control group were compared. Univariate and multivariate binary logistic regression tests were conducted to identify potential risk factors for respiratory infections in pSS-ILD patients.

Results

Among 162 pSS-ILD patients, 32.72% (53/162) suffered from respiratory infections. The most frequent type of ILD was nonspecific interstitial pneumonia (32.08%, 51/159), and the most common type of pathogen was bacteria (64.25%, 34/53). Infection group showed higher levels of ESSDAI (P < 0.001), CRP (P < 0.001), ESR (P = 0.003), and C3 (P = 0.020) but lower level of DLCO-SB (P = 0.015). Univariate logistic model revealed that PAH and the use of glucocorticoid increased infection risk in pSS-ILD patients. On multivariate logistic regression analysis, PAH (OR = 3.993, 95% CI = 1.192–13.373, P = 0.025) and severe reduction of DLCO (DLCO-SB < 40%, OR = 4.625, 95% CI = 1.281–16.702, P = 0.019) were significantly associated with increased risk of respiratory infections in pSS-ILD patients.

Conclusion

Among pSS-ILD patients, the most frequent type of ILD was nonspecific interstitial pneumonia. In patients with infection, bacteria were the most common pathogen. Higher levels of ESSDAI, CRP, ESR, and C3 may be correlated with increased infection risk. PAH and reduction of DLCO were identified as independent risk factors.
Key Points
• ILD and infectious diseases severely affect pSS patient conditions.
• Higher levels of ESSDAI, CRP, ESR, and C3 may be correlated with increased infection risks in pSS-ILD.
• PAH and reduction of DLCO were identified as independent risk factors for lower respiratory infection.
Literatur
1.
Zurück zum Zitat Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 11(3):229CrossRefPubMedPubMedCentral Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 11(3):229CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Palm O, Garen T, Berge Enger T et al (2013) Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality--a retrospective study based on registry data. Rheumatology (Oxford, England). 52(1):173–179CrossRefPubMed Palm O, Garen T, Berge Enger T et al (2013) Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality--a retrospective study based on registry data. Rheumatology (Oxford, England). 52(1):173–179CrossRefPubMed
3.
Zurück zum Zitat American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002) This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165(2):277–304 American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002) This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165(2):277–304
4.
Zurück zum Zitat Wang Y, Hou Z, Qiu M et al (2018) Risk factors for primary Sjgren syndrome-associated interstitial lung disease. J Thorac Dis 10(4):2108–2117CrossRefPubMedPubMedCentral Wang Y, Hou Z, Qiu M et al (2018) Risk factors for primary Sjgren syndrome-associated interstitial lung disease. J Thorac Dis 10(4):2108–2117CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Meyer-Olson D, Witte T (2011) Immunology: prevention of infections in patients with autoimmune diseases. Nat Rev Rheumatol 7(4):198–200CrossRefPubMed Meyer-Olson D, Witte T (2011) Immunology: prevention of infections in patients with autoimmune diseases. Nat Rev Rheumatol 7(4):198–200CrossRefPubMed
6.
Zurück zum Zitat Pease C, Pope JE, Truong D et al (2012) Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. Semin Arthritis Rheum 41(1):81–89CrossRef Pease C, Pope JE, Truong D et al (2012) Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. Semin Arthritis Rheum 41(1):81–89CrossRef
7.
Zurück zum Zitat Fox RI, Fox CM (2011) Sjögren’s syndrome: infections that may play a role in pathogenesis, mimic the disease, or complicate the patient’s course. Indian J Rheumatol 6(1):13–25CrossRef Fox RI, Fox CM (2011) Sjögren’s syndrome: infections that may play a role in pathogenesis, mimic the disease, or complicate the patient’s course. Indian J Rheumatol 6(1):13–25CrossRef
8.
Zurück zum Zitat Woodhead M, Blasi F, Ewig S et al (2011) Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect 17(Suppl 6):E1–E59CrossRefPubMedPubMedCentral Woodhead M, Blasi F, Ewig S et al (2011) Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect 17(Suppl 6):E1–E59CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Miller JM, Binnicker MJ, Campbell S et al (2018) A guide to utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 67(6):e1–e94CrossRefPubMed Miller JM, Binnicker MJ, Campbell S et al (2018) A guide to utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 67(6):e1–e94CrossRefPubMed
10.
Zurück zum Zitat Luppi F, Sebastiani M, Silva M et al (2020) Interstitial lung disease in Sjögren’s syndrome: a clinical review. Clin Exp Rheumatol 38:291–300PubMed Luppi F, Sebastiani M, Silva M et al (2020) Interstitial lung disease in Sjögren’s syndrome: a clinical review. Clin Exp Rheumatol 38:291–300PubMed
12.
Zurück zum Zitat Mathieu A, Cauli A, Pala R et al (1995) Tracheo-bronchial mucociliary clearance in patients with primary and secondary Sjögren’s syndrome. Scand J Rheumatol 24(5):300–304CrossRefPubMed Mathieu A, Cauli A, Pala R et al (1995) Tracheo-bronchial mucociliary clearance in patients with primary and secondary Sjögren’s syndrome. Scand J Rheumatol 24(5):300–304CrossRefPubMed
13.
Zurück zum Zitat Newball HH, Brahim SA (1977) Chronic obstructive airway disease in patients with Sjögren’s syndrome. Am Rev Respir Dis 115(2):295–304PubMed Newball HH, Brahim SA (1977) Chronic obstructive airway disease in patients with Sjögren’s syndrome. Am Rev Respir Dis 115(2):295–304PubMed
14.
Zurück zum Zitat Soto-Cardenas MJ, Perez-De-Lis M, Bove A et al (2010) Bronchiectasis in primary Sjögren’s syndrome: prevalence and clinical significance. Clin Exp Rheumatol 28(5):647–653PubMed Soto-Cardenas MJ, Perez-De-Lis M, Bove A et al (2010) Bronchiectasis in primary Sjögren’s syndrome: prevalence and clinical significance. Clin Exp Rheumatol 28(5):647–653PubMed
15.
Zurück zum Zitat Fairfax AJ, Haslam PL, Pavia D et al (1981) Pulmonary disorders associated with Sjögren’s syndrome. Q J Med 50(199):279–295PubMed Fairfax AJ, Haslam PL, Pavia D et al (1981) Pulmonary disorders associated with Sjögren’s syndrome. Q J Med 50(199):279–295PubMed
16.
Zurück zum Zitat Kelly C, Gardiner P, Pal B et al (1991) Lung function in primary Sjögren’s syndrome: a cross sectional and longitudinal study. Thorax 46(3):180–183CrossRefPubMedPubMedCentral Kelly C, Gardiner P, Pal B et al (1991) Lung function in primary Sjögren’s syndrome: a cross sectional and longitudinal study. Thorax 46(3):180–183CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat García-Carrasco M, Ramos-Casals M, Rosas J et al (2002) Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine 81(4):270–280CrossRefPubMed García-Carrasco M, Ramos-Casals M, Rosas J et al (2002) Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine 81(4):270–280CrossRefPubMed
18.
Zurück zum Zitat Zhang T, Yuan F, Xu L et al (2020) Characteristics of patients with primary Sjögren’s syndrome associated interstitial lung disease and relevant features of disease progression. Clin Rheumatol 39(5):1561–1568CrossRefPubMed Zhang T, Yuan F, Xu L et al (2020) Characteristics of patients with primary Sjögren’s syndrome associated interstitial lung disease and relevant features of disease progression. Clin Rheumatol 39(5):1561–1568CrossRefPubMed
20.
Zurück zum Zitat Almirall J, Serra-Prat M, Bolíbar I et al (2017) Risk factors for community-acquired pneumonia in adults: a systematic review of observational studies. Respiration 94(3):299–311CrossRefPubMed Almirall J, Serra-Prat M, Bolíbar I et al (2017) Risk factors for community-acquired pneumonia in adults: a systematic review of observational studies. Respiration 94(3):299–311CrossRefPubMed
21.
Zurück zum Zitat Danza Á, Graña D, Goñi M et al (2016) Hydroxychloroquine for autoimmune diseases. Rev Med Chil 144(2):232–240CrossRefPubMed Danza Á, Graña D, Goñi M et al (2016) Hydroxychloroquine for autoimmune diseases. Rev Med Chil 144(2):232–240CrossRefPubMed
22.
23.
Zurück zum Zitat Tishler M, Yaron I, Shirazi I et al (1999) Hydroxychloroquine treatment for primary Sjögren’s syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 58(4):253–256CrossRefPubMedPubMedCentral Tishler M, Yaron I, Shirazi I et al (1999) Hydroxychloroquine treatment for primary Sjögren’s syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 58(4):253–256CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Yao X, Ye F, Zhang M et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71(15):732–739CrossRefPubMed Yao X, Ye F, Zhang M et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71(15):732–739CrossRefPubMed
25.
Zurück zum Zitat Rogliani P, Calzetta L, Cavalli F et al (2016) Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Pulm Pharmacol Ther 40:95–103CrossRef Rogliani P, Calzetta L, Cavalli F et al (2016) Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Pulm Pharmacol Ther 40:95–103CrossRef
26.
Zurück zum Zitat Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824CrossRefPubMedPubMedCentral Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Muramatsu Y, Sugino K, Ishida F et al (2016) Effect of inhaled N-acetylcysteine monotherapy on lung function and redox balance in idiopathic pulmonary fibrosis. Respir Investig 54(3):170–178CrossRefPubMed Muramatsu Y, Sugino K, Ishida F et al (2016) Effect of inhaled N-acetylcysteine monotherapy on lung function and redox balance in idiopathic pulmonary fibrosis. Respir Investig 54(3):170–178CrossRefPubMed
28.
Zurück zum Zitat Mathai SC, Danoff SK (2016) Management of interstitial lung disease associated with connective tissue disease. BMJ (Clinical research ed). 352:h6819PubMedPubMedCentral Mathai SC, Danoff SK (2016) Management of interstitial lung disease associated with connective tissue disease. BMJ (Clinical research ed). 352:h6819PubMedPubMedCentral
29.
Zurück zum Zitat Raghu G, Remy-Jardin M, Richeldi L et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 205(9):e18–e47CrossRefPubMedPubMedCentral Raghu G, Remy-Jardin M, Richeldi L et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 205(9):e18–e47CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Martinez FJ, de Andrade JA, Anstrom KJ et al (2014) Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2093–2101CrossRefPubMedPubMedCentral Martinez FJ, de Andrade JA, Anstrom KJ et al (2014) Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2093–2101CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Shi H, Yin D, Bonella F et al (2020) Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis. BMC Pulm Med 20(1):128CrossRefPubMedPubMedCentral Shi H, Yin D, Bonella F et al (2020) Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis. BMC Pulm Med 20(1):128CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Zhou X, Liu Y, Jin Y et al (2021) Immune responses after influenza vaccination in patients of primary Sjögren’s syndrome. Rheumatology (Oxford, England). 60(1):224–230CrossRefPubMed Zhou X, Liu Y, Jin Y et al (2021) Immune responses after influenza vaccination in patients of primary Sjögren’s syndrome. Rheumatology (Oxford, England). 60(1):224–230CrossRefPubMed
33.
Zurück zum Zitat Singh JA, Saag KG, Bridges SL Jr et al (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol (Hoboken, NJ). 68(1):1–26 Singh JA, Saag KG, Bridges SL Jr et al (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis  Rheumatol (Hoboken, NJ). 68(1):1–26
34.
Zurück zum Zitat Furer V, Rondaan C, Heijstek MW et al (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(1):39–52CrossRefPubMed Furer V, Rondaan C, Heijstek MW et al (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(1):39–52CrossRefPubMed
35.
Zurück zum Zitat Murdaca G, Orsi A, Spanò F et al (2016) Vaccine-preventable infections in systemic lupus erythematosus. Hum Vaccin Immunother 12(3):632–643CrossRef Murdaca G, Orsi A, Spanò F et al (2016) Vaccine-preventable infections in systemic lupus erythematosus. Hum Vaccin Immunother 12(3):632–643CrossRef
Metadaten
Titel
Respiratory infection risk in primary Sjögren’s syndrome complicated with interstitial lung disease: a retrospective study
verfasst von
Xingyu Zhou
Hao Li
Naidi Wang
Yuebo Jin
Jing He
Publikationsdatum
13.12.2023
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 2/2024
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-023-06803-5

Weitere Artikel der Ausgabe 2/2024

Clinical Rheumatology 2/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.